PMID- 19303976
OWN - NLM
STAT- MEDLINE
DCOM- 20090420
LR  - 20131121
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
VI  - 58
IP  - 4
DP  - 2009 Apr
TI  - The Pro12Ala polymorphism of the PPARgamma2 gene is associated with hepatic 
      glucose uptake during hyperinsulinemia in subjects with type 2 diabetes mellitus.
PG  - 541-6
LID - 10.1016/j.metabol.2008.11.015 [doi]
AB  - The Ala12 allele of the peroxisome proliferator-activated receptor gamma gene 
      (PPARG2) has been associated with reduced risk of type 2 diabetes mellitus (T2DM) 
      and increased whole-body and skeletal muscle insulin sensitivity in nondiabetic 
      subjects. The effect of the Pro12Ala polymorphism on tissue specific insulin 
      sensitivity in subjects with T2DM has not been previously investigated. We 
      studied the effect of the Pro12Ala polymorphism on the rates of whole-body, 
      skeletal muscle, and subcutaneous adipose tissue glucose uptake (GU) in T2DM 
      subjects, and the rates of hepatic GU in nondiabetic and T2DM subjects during 
      hyperinsulinemia. Our study included 105 T2DM subjects whose whole-body, skeletal 
      muscle, subcutaneous adipose tissue, and hepatic GUs were measured using 
      (18)F-fluorodeoxyglucose and positron emission tomography during the 
      hyperinsulinemic euglycemic clamp. Hepatic GU was also measured in 68 nondiabetic 
      subjects. In obese (body mass index >or=27 kg/m(2)) subjects with T2DM, the rate 
      of hepatic GU was 28% lower in subjects with the Pro12Pro genotype than in 
      carriers of the Ala12 allele (P = .001); and a similar trend was observed in 
      nondiabetic obese subjects (P = .137). No effect of the Pro12Ala polymorphism on 
      the rates of whole-body, skeletal muscle, or subcutaneous adipose tissue GU was 
      observed in T2DM subjects. We conclude that the Ala12 allele of PPARG2 is 
      associated with higher hepatic GU in obese subjects with T2DM.
FAU - Honka, Miikka-Juhani
AU  - Honka MJ
AD  - Turku PET Centre, University of Turku, 20521 Turku, Finland.
FAU - Vanttinen, Markku
AU  - Vanttinen M
FAU - Iozzo, Patricia
AU  - Iozzo P
FAU - Virtanen, Kirsi A
AU  - Virtanen KA
FAU - Lautamaki, Riikka
AU  - Lautamaki R
FAU - Hallsten, Kirsti
AU  - Hallsten K
FAU - Borra, Ronald J H
AU  - Borra RJ
FAU - Takala, Teemu
AU  - Takala T
FAU - Viljanen, Antti P M
AU  - Viljanen AP
FAU - Kemppainen, Jukka
AU  - Kemppainen J
FAU - Pihlajamaki, Jussi
AU  - Pihlajamaki J
FAU - Knuuti, Juhani
AU  - Knuuti J
FAU - Nuutila, Pirjo
AU  - Nuutila P
FAU - Laakso, Markku
AU  - Laakso M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (PPAR gamma)
RN  - 9DLQ4CIU6V (Proline)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Adult
MH  - Alanine/*genetics
MH  - Diabetes Mellitus, Type 2/genetics/*metabolism
MH  - Female
MH  - Humans
MH  - Hyperinsulinism/genetics/*metabolism
MH  - Male
MH  - PPAR gamma/*genetics
MH  - *Polymorphism, Genetic
MH  - Proline/*genetics
EDAT- 2009/03/24 09:00
MHDA- 2009/04/21 09:00
CRDT- 2009/03/24 09:00
PHST- 2008/06/28 00:00 [received]
PHST- 2008/11/11 00:00 [accepted]
PHST- 2009/03/24 09:00 [entrez]
PHST- 2009/03/24 09:00 [pubmed]
PHST- 2009/04/21 09:00 [medline]
AID - S0026-0495(08)00433-2 [pii]
AID - 10.1016/j.metabol.2008.11.015 [doi]
PST - ppublish
SO  - Metabolism. 2009 Apr;58(4):541-6. doi: 10.1016/j.metabol.2008.11.015.